FOLD
Amicus Therapeutics, Inc. [FOLD] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
FOLD Stock Summary
Top 10 Correlated ETFs
FOLD
Top 10 Correlated Stocks
FOLD
In the News
FOLD Financial details
Company Rating
Neutral
Market Cap
3.15B
Income
-151.58M
Revenue
399.36M
Book val./share
0.55
Cash/share
0.97
Dividend
-
Dividend %
-
Employees
517
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-22.7
Forward P/E
-
PEG
6.27
P/S
8.67
P/B
21.48
P/C
10.68
P/FCF
-45.24
Quick Ratio
2.23
Current Ratio
2.88
Debt / Equity
2.47
LT Debt / Equity
2.42
-
-
EPS (TTM)
-0.52
EPS next Y
-
EPS next Q
-
EPS this Y
-37.8%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-19.19%
Revenue last 5Y
16.99%
Revenue Q/Q
11.19%
EPS Q/Q
64.38%
-
-
-
-
SMA20
-8.33%
SMA50
-15.38%
SMA100
-
Inst Own
70.13%
Inst Trans
0.67%
ROA
-19%
ROE
-119%
ROC
-0.13%
Gross Margin
90%
Oper. Margin
-19%
Profit Margin
-38%
Payout
-2%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.7-14.57
52W High
-26.04%
52W Low
+15.06%
RSI
29
Rel Volume
0.22
Avg Volume
3.06M
Volume
685.25K
Perf Week
-8.12%
Perf Month
-15.74%
Perf Quarter
-4.65%
Perf Half Y
-1.94%
-
-
-
-
Beta
0.756
-
-
Volatility
0.25%, 0.5%
Prev Close
-1.85%
Price
10.355
Change
-2.4%
FOLD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.76 | 1.01 | 1.13 | 1.14 | 1.35 | |
| Net income per share | -1.48 | -1.07 | -0.92 | -0.82 | -0.51 | |
| Operating cash flow per share | -1.04 | -0.9 | -0.75 | -0.58 | -0.23 | |
| Free cash flow per share | -1.12 | -0.91 | -0.76 | -0.59 | -0.26 | |
| Cash per share | 1.88 | 1.87 | 1.78 | 1.02 | 0.97 | |
| Book value per share | 1.98 | 1.11 | 1.13 | 0.43 | 0.54 | |
| Tangible book value per share | 1.06 | 0.25 | 0.32 | -0.34 | -0.2 | |
| Share holders equity per share | 1.98 | 1.11 | 1.13 | 0.43 | 0.54 | |
| Interest debt per share | 0.95 | 1.79 | 1.74 | 1.69 | 1.51 | |
| Market cap | 2.34B | 5.98B | 3.13B | 3.53B | 4.19B | |
| Enterprise value | 2.41B | 6.26B | 3.33B | 3.83B | 4.39B | |
| P/E ratio | -6.57 | -21.59 | -12.52 | -14.92 | -27.63 | |
| Price to sales ratio | 12.85 | 22.91 | 10.26 | 10.72 | 10.49 | |
| POCF ratio | -9.35 | -25.62 | -15.48 | -21.19 | -60.62 | |
| PFCF ratio | -8.66 | -25.27 | -15.19 | -20.72 | -54.73 | |
| P/B Ratio | 4.92 | 20.87 | 10.2 | 28.68 | 26.15 | |
| PTB ratio | 4.92 | 20.87 | 10.2 | 28.68 | 26.15 | |
| EV to sales | 13.22 | 23.98 | 10.9 | 11.64 | 10.98 | |
| Enterprise value over EBITDA | -7.32 | -26.9 | -16.98 | -19.97 | -66.85 | |
| EV to operating cash flow | -9.62 | -26.82 | -16.44 | -23.01 | -63.49 | |
| EV to free cash flow | -8.91 | -26.45 | -16.13 | -22.5 | -57.32 | |
| Earnings yield | -0.15 | -0.05 | -0.08 | -0.07 | -0.04 | |
| Free cash flow yield | -0.12 | -0.04 | -0.07 | -0.05 | -0.02 | |
| Debt to equity | 0.44 | 1.54 | 1.43 | 3.67 | 2.47 | |
| Debt to assets | 0.25 | 0.5 | 0.49 | 0.62 | 0.51 | |
| Net debt to EBITDA | -0.2 | -1.2 | -0.99 | -1.58 | -3.02 | |
| Current ratio | 4.04 | 4.47 | 4.09 | 3.05 | 2.88 | |
| Interest coverage | -15.94 | -10.87 | -6.16 | -5.51 | -1.47 | |
| Income quality | 0.7 | 0.84 | 0.81 | 0.7 | 0.46 | |
| Dividend Yield | 0 | 0.01 | 0 | 0 | 0 | |
| Payout ratio | -0.01 | -0.12 | -0.06 | -0.02 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 1.57 | 1.18 | 0.89 | 0.84 | 0.38 | |
| Intangibles to total assets | 0.26 | 0.25 | 0.24 | 0.3 | 0.28 | |
| Capex to operating cash flow | 0.08 | 0.01 | 0.02 | 0.02 | 0.11 | |
| Capex to revenue | -0.11 | -0.01 | -0.01 | -0.01 | -0.02 | |
| Capex to depreciation | -4.19 | -0.36 | -0.63 | -0.7 | -0.95 | |
| Stock based compensation to revenue | 0.24 | 0.19 | 0.19 | 0.23 | 0.22 | |
| Graham number | 8.13 | 5.16 | 4.85 | 2.8 | 2.5 | |
| ROIC | -0.4 | -0.32 | -0.26 | -0.31 | -0.12 | |
| Return on tangible assets | -0.57 | -0.42 | -0.37 | -0.47 | -0.27 | |
| Graham Net | 0.46 | -0.28 | -0.23 | -0.85 | -0.8 | |
| Working capital | 391.26M | 449.79M | 450.86M | 284.8M | 315.37M | |
| Tangible asset value | 255.63M | 65.58M | 86.57M | -97.75M | -58.11M | |
| Net current asset value | 146.29M | -20.67M | -937K | -177.3M | -134.65M | |
| Invested capital | 0.44 | 1.54 | 1.43 | 3.67 | 2.47 | |
| Average receivables | 27.62M | 40.1M | 49.8M | 59.43M | 76.91M | |
| Average payables | 100.5M | 68.72M | 19.29M | 18.46M | 15.27M | |
| Average inventory | 11.22M | 16.8M | 23.19M | 25.32M | 41.76M | |
| Days sales outstanding | 66.66 | 65.65 | 62.93 | 73.39 | 80.09 | |
| Days payables outstanding | 2K | 200.62 | 227.83 | 145.75 | 122.1 | |
| Days of inventory on hand | 233.35 | 229.93 | 284.01 | 225.21 | 482.07 | |
| Receivables turnover | 5.48 | 5.56 | 5.8 | 4.97 | 4.56 | |
| Payables turnover | 0.18 | 1.82 | 1.6 | 2.5 | 2.99 | |
| Inventory turnover | 1.56 | 1.59 | 1.29 | 1.62 | 0.76 | |
| ROE | -0.75 | -0.97 | -0.81 | -1.92 | -0.95 | |
| Capex per share | -0.08 | -0.01 | -0.01 | -0.01 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.31 | 0.3 | 0.32 | 0.35 | 0.39 | |
| Net income per share | -0.2 | -0.18 | -0.15 | -0.07 | -0.12 | |
| Operating cash flow per share | -0.29 | -0.06 | -0.06 | -0.13 | 0.01 | |
| Free cash flow per share | -0.3 | -0.07 | -0.06 | -0.13 | 0.01 | |
| Cash per share | 1.04 | 0.92 | 0.91 | 0.95 | 0.97 | |
| Book value per share | 0.44 | 0.35 | 0.38 | 0.45 | 0.55 | |
| Tangible book value per share | -0.35 | -0.41 | -0.37 | -0.29 | -0.2 | |
| Share holders equity per share | 0.44 | 0.35 | 0.38 | 0.45 | 0.55 | |
| Interest debt per share | 1.65 | 1.59 | 1.59 | 1.49 | 1.39 | |
| Market cap | 3.43B | 3.23B | 3.68B | 3.6B | 4.17B | |
| Enterprise value | 3.74B | 3.52B | 3.92B | 3.79B | 4.36B | |
| P/E ratio | -15.36 | -15.26 | -21.27 | -41.67 | -30.78 | |
| Price to sales ratio | 38.96 | 37.45 | 38.91 | 34.75 | 36.2 | |
| POCF ratio | -42.49 | -178.81 | -227.95 | -93.79 | 1.2K | |
| PFCF ratio | -41.13 | -161.46 | -200.57 | -90.11 | 2.41K | |
| P/B Ratio | 27.89 | 31.5 | 32.96 | 26.99 | 26.01 | |
| PTB ratio | 27.89 | 31.5 | 32.96 | 26.99 | 26.01 | |
| EV to sales | 42.4 | 40.83 | 41.46 | 36.59 | 37.92 | |
| Enterprise value over EBITDA | -66.6 | -88.35 | -160.93 | -129.67 | -2.89K | |
| EV to operating cash flow | -46.25 | -194.94 | -242.88 | -98.77 | 1.26K | |
| EV to free cash flow | -44.77 | -176.02 | -213.71 | -94.89 | 2.53K | |
| Earnings yield | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | |
| Free cash flow yield | -0.02 | -0.01 | 0 | -0.01 | 0 | |
| Debt to equity | 3.67 | 4.41 | 4.05 | 3.41 | 2.47 | |
| Debt to assets | 0.62 | 0.65 | 0.62 | 0.59 | 0.51 | |
| Net debt to EBITDA | -5.41 | -7.31 | -9.89 | -6.54 | -131.17 | |
| Current ratio | 3.05 | 2.89 | 2.72 | 2.73 | 2.88 | |
| Interest coverage | -3.67 | -3.16 | -1.51 | 1.31 | -0.29 | |
| Income quality | 1.45 | 0.34 | 0.37 | 1.78 | -0.1 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.02 | 0 | -0.03 | -0.11 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.73 | 0.48 | 0.37 | 0.39 | 0.3 | |
| Intangibles to total assets | 0.3 | 0.32 | 0.3 | 0.29 | 0.28 | |
| Capex to operating cash flow | 0.03 | 0.11 | 0.14 | 0.04 | -0.5 | |
| Capex to revenue | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | |
| Capex to depreciation | -2.04 | -1.54 | -1 | -0.7 | -0.79 | |
| Stock based compensation to revenue | 0.21 | 0.4 | 0.18 | 0.16 | 0.16 | |
| Graham number | 1.4 | 1.2 | 1.13 | 0.86 | 1.19 | |
| ROIC | -0.05 | -0.06 | -0.03 | -0.03 | -0.01 | |
| Return on tangible assets | -0.11 | -0.11 | -0.08 | -0.04 | -0.06 | |
| Graham Net | -0.88 | -0.91 | -0.95 | -0.9 | -0.8 | |
| Working capital | 284.8M | 261.31M | 273.59M | 293.8M | 315.37M | |
| Tangible asset value | -97.75M | -118.19M | -108.36M | -85.88M | -58.11M | |
| Net current asset value | -177.3M | -198.25M | -185.69M | -167.59M | -134.65M | |
| Invested capital | 3.67 | 4.41 | 4.05 | 3.41 | 2.47 | |
| Average receivables | 59.25M | 67.19M | 65.95M | 68.52M | 80.48M | |
| Average payables | 13.73M | 20.19M | 19.24M | 18.34M | 19.14M | |
| Average inventory | 18.54M | 25.41M | 39.19M | 54.16M | 58.32M | |
| Days sales outstanding | 67.63 | 71.13 | 60.68 | 63.77 | 68.53 | |
| Days payables outstanding | 147.82 | 323.66 | 133.53 | 209.52 | 100.76 | |
| Days of inventory on hand | 228.41 | 350.1 | 507.38 | 515.21 | 397.8 | |
| Receivables turnover | 1.33 | 1.27 | 1.48 | 1.41 | 1.31 | |
| Payables turnover | 0.61 | 0.28 | 0.67 | 0.43 | 0.89 | |
| Inventory turnover | 0.39 | 0.26 | 0.18 | 0.17 | 0.23 | |
| ROE | -0.45 | -0.52 | -0.39 | -0.16 | -0.21 | |
| Capex per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
FOLD Frequently Asked Questions
What is Amicus Therapeutics, Inc. stock symbol ?
Amicus Therapeutics, Inc. is a US stock , located in Philadelphia of Pa and trading under the symbol FOLD
What is Amicus Therapeutics, Inc. stock quote today ?
Amicus Therapeutics, Inc. stock price is $10.355 today.
Is Amicus Therapeutics, Inc. stock public?
Yes, Amicus Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 3.06M
- Market Capitalization 3.15B
- Employee 517
- CEO Mr. Bradley L. Campbell M.B.A.
- Headquarters Philadelphia,PA,US
- IPO Date 2007-05-31
-
Website
https://amicusrx.com 
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
